The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Call for Grant Applications (CGA): Clinical Advances in Merkel Cell Carcinoma (MCC) Supporting Local and Regional Activities for Community Oncologists
Pfizer - Independent Grants for Learning & Change (IGLC) and EMD Serono Global Medical Education (GME) are collaborating to provide grant support for continuing professional education in the area of Immuno-Oncology.
MCC is a rare and aggressive disease in which cancer cells form in the top layer of the skin, close to nerve endings. MCC, which is also known as neuroendocrine carcinoma of the skin or trabecular cancer, often starts in those areas of skin that are most often exposed to the sun, including the head and neck, arms, legs, and trunk. Risk factors for MCC include sun exposure and having a weak immune system. Solid organ transplant recipients, people with HIV/AIDS and people with other cancers, such as chronic lymphocytic leukemia, are at higher risk. Caucasian males over age 50 are also at increased risk. MCC tends to metastasize at an early stage, spreading initially to nearby lymph nodes, and then potentially to more distant areas in the body, including other lymph nodes or areas of skin, lungs, brain, bones or other organs. Current treatment options for MCC include surgery, radiation and chemotherapy. Treatment for metastatic or Stage IV MCC is generally palliative. A variety of investigative immunotherapy options for MCC are being explored worldwide.
Pfizer IGLC and EMD Serono GME are collaborating to support independent education for community oncologists that focuses on increasing the awareness and detection of MCC, managing immunemediated adverse reactions, and advancing the understanding of emerging treatment options for patients with MCC, including, without limitation, immunotherapy.
This CGA is requesting grant applications for proposals that will help community oncologists stay abreast of emerging data in MCC and emerging treatment options. Proposals may include activities such as:
- On-agenda sessions at established conferences
- Mini symposia alongside established conferences
- Regional live meetings, workshops, grand rounds, tumor board presentations, etc.
- Online tools, printed handouts, and other enduring materials
Deadline: Apr. 5, 2017
The following organizations may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
Important note for this CGA: US organizations must be accredited providers of continuing medical education and cannot be physicianowned clinics, managed care organization or pharmacy benefit managers.
All activities must be “independent” which means free from the influence or control of any commercial entity. Activities must also be accredited/certified for CME/CE credit.
Proposals requesting up to a maximum of $75,000 USD will be considered. Smaller educational grant requests in the $5K to $25K range are strongly encouraged. The total available budget related to this CGA is $200,000 USD.